Phuturdex › Diseases › Adenocarcinoma
Drugs in development · updated 30 October 2026
Adenocarcinoma: drugs in development
As of 30 October 2026 there are 89 active clinical trials (recruiting or ongoing, phases I–III) on 111 drugs for adenocarcinoma. 52 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
Sorted by most advanced phase and number of active trials. Showing 40 of 52 drugs.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| OxaliplatinOxaliplatine, Oxaliplain | II–III | 19 | NCT04208347 |
| PembrolizumabKEYTRUDA, MK-3475 | III | 13 | NCT07673887 |
| CapecitabineXeloda, Capectitabine Tablets | III | 11 | NCT07673887 |
| DocetaxelTaxotere, Beizray® | III | 8 | NCT06592924 |
| Fluorouracil5-Fluorouracil, Adrucil | III | 8 | NCT06901531 |
| LeucovorinFolinic acid, l-leucovorin | III | 8 | NCT07673887 |
| GemcitabineGemcitabin, Gemzar | III | 6 | NCT06908304 |
| PaclitaxelTaxol, Paxlitaxel | III | 6 | NCT04704934 |
| CemiplimabREGN2810, Libtayo® | III | 5 | NCT06908304 |
| EnzalutamideDeutenzalutamide, Xtandi | III | 5 | NCT06592924 |
| RamucirumabCyramza® | III | 4 | NCT04704934 |
| ZolbetuximabVyloy® | III | 4 | NCT06901531 |
| CisplatinCis Platinum, Cisplatine | III | 3 | NCT06564844 |
| DarolutamideNubeqa, ODM-201 | III | 3 | NCT06592924 |
| NivolumabOpdivo, ONO-4538 | III | 3 | NCT07431281 |
Sorted by most advanced phase and number of active trials. Showing 15 of 59 drugs.
All 111 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Hepatocellular carcinoma 266 drugs
- Renal cell carcinoma 228 drugs
- Cholangiocarcinoma 136 drugs
- Non-small-cell lung carcinoma 726 drugs
- Colorectal neoplasm 534 drugs
- Melanoma 352 drugs
- Metastasis 493 drugs
- Ovarian neoplasm 411 drugs
- Head and neck squamous cell carcinoma 321 drugs
- Lung neoplasm 348 drugs
- Neoplasm 671 drugs
- Kidney neoplasm 92 drugs
Broader categories
- Glandular and epithelial neoplasm 12 drugs
- Carcinoma 137 drugs
- Neoplasm 671 drugs
- Digestive System Diseases 36 drugs
- Digestive system neoplasm 37 drugs
- Urogenital Diseases 16 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D000230 “Adenocarcinoma”.